Dear Reader,Our scanners just identified several healthtech stocks that are expected to release earnings starting November 8th.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
22nd Century
Symbol: XXII
Recent Price: $1.27
Average Analyst Price Target: $6.75 (431.50%)
Market Cap: $262.04M
Last Year's EPS: -$0.06
Consensus EPS Forecast: -$0.06
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: James McIlree, analyst at Dawson James, reiterates coverage on 22nd Century (XXII) in the Healthcare sector with a Buy rating and a price target of $ 8.5 (1 month ago).
TipRanks.com also reports that 22nd Century currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $6.75 . The target pricing ranges from a high forecast of $8.50 down to a low forecast of $5.00. 22nd Century (XXII)’s last closing price was $1.27 which would put the average price target at 431.50% upside.Here are 3rd party ratings for XXII:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Bottom 37% (157 out of 251)
--------------------------------------------------------------------------
AbCellera Biologics
Symbol: ABCL
Recent Price: $11.91
Average Analyst Price Target: $33.00 (177.08%)
Market Cap: $3.45B
Last Year's EPS: -$0.08
Consensus EPS Forecast: $0.06
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Gaurav Goparaju, analyst at Berenberg Bank, reiterates coverage on AbCellera Biologics (ABCL) in the Healthcare sector with a Buy rating and a price target of $ 43 (2 days ago).
TipRanks.com also reports that AbCellera Biologics currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $33.00 . The target pricing ranges from a high forecast of $43.00 down to a low forecast of $14.00. AbCellera Biologics (ABCL)’s last closing price was $11.91 which would put the average price target at 177.08% upside.Here are 3rd party ratings for ABCL:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 20% (51 out of 251)
--------------------------------------------------------------------------
Achilles Therapeutics
Symbol: ACHL
Recent Price: $1.95
Average Analyst Price Target: $20.00 (925.64%)
Market Cap: $78.69M
Last Year's EPS: -$0.34
Consensus EPS Forecast: -$0.65
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Geulah Livshits, analyst at Chardan Capital, reiterates coverage on Achilles Therapeutics (ACHL) in the Healthcare sector with a Buy rating and a price target of $ 20 (2 months ago).
TipRanks.com also reports that Achilles Therapeutics currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $20.00 . The target pricing ranges from a high forecast of $20.00 down to a low forecast of $20.00. Achilles Therapeutics (ACHL)’s last closing price was $1.95 which would put the average price target at 925.64% upside.Here are 3rd party ratings for ACHL:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 20% (51 out of 251)
--------------------------------------------------------------------------
Aclaris Therapeutics
Symbol: ACRS
Recent Price: $15.16
Average Analyst Price Target: $41.00 (170.45%)
Market Cap: $1.02B
Last Year's EPS: -$0.35
Consensus EPS Forecast: -$0.39
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Julian Harrison, analyst at BTIG, reiterates coverage on Aclaris Therapeutics (ACRS) in the Healthcare sector with a Buy rating and a price target of $ 32 (4 weeks ago).
TipRanks.com also reports that Aclaris Therapeutics currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $41.00 . The target pricing ranges from a high forecast of $50.00 down to a low forecast of $32.00. Aclaris Therapeutics (ACRS)’s last closing price was $15.16 which would put the average price target at 170.45% upside.Here are 3rd party ratings for ACRS:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 31% (79 out of 251)
--------------------------------------------------------------------------
Adaptimmune Therapeutics
Symbol: ADAP
Recent Price: $1.6
Average Analyst Price Target: $5.50 (243.75%)
Market Cap: $246.69M
Last Year's EPS: -$0.05
Consensus EPS Forecast: -$0.28
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Mara Goldstein, analyst at Mizuho Securities, reiterates coverage on Adaptimmune Therapeutics (ADAP) in the Healthcare sector with a Hold rating and a price target of $ 9 (1 week ago).
TipRanks.com also reports that Adaptimmune Therapeutics currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $5.50 . The target pricing ranges from a high forecast of $10.00 down to a low forecast of $1.50. Adaptimmune Therapeutics (ADAP)’s last closing price was $1.6 which would put the average price target at 243.75% upside.Here are 3rd party ratings for ADAP:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 20% (51 out of 251)
--------------------------------------------------------------------------
ADC Therapeutics
Symbol: ADCT
Recent Price: $4.23
Average Analyst Price Target: $15.50 (266.43%)
Market Cap: $335.66M
Last Year's EPS: -$0.93
Consensus EPS Forecast: -$0.35
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Gregory Renza, analyst at RBC Capital, reiterates coverage on ADC Therapeutics (ADCT) in the Healthcare sector with a Buy rating and a price target of $ 25 (4 weeks ago).
TipRanks.com also reports that ADC Therapeutics currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $15.50 . The target pricing ranges from a high forecast of $25.00 down to a low forecast of $5.00. ADC Therapeutics (ADCT)’s last closing price was $4.23 which would put the average price target at 266.43% upside.Here are 3rd party ratings for ADCT:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Strong Buy, Top 20% (51 out of 251)
--------------------------------------------------------------------------
Agenus
Symbol: AGEN
Recent Price: $2.44
Average Analyst Price Target: $8.00 (227.87%)
Market Cap: $696.58M
Last Year's EPS: $0.72
Consensus EPS Forecast: -$0.19
Expected Earnings Date: Nov 07 2022
Recent Analyst Action: Mayank Mamtani, analyst at B.Riley Financial, reiterates coverage on Agenus (AGEN) in the Healthcare sector with a Buy rating and a price target of $ 8 (3 weeks ago).
TipRanks.com also reports that Agenus currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.00 . The target pricing ranges from a high forecast of $8.00 down to a low forecast of $8.00. Agenus (AGEN)’s last closing price was $2.44 which would put the average price target at 227.87% upside.Here are 3rd party ratings for AGEN:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Buy, Top 20% (51 out of 251)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
